指南与共识心律失常

2018 AHA 高级心血管生命支持聚焦更新:心脏骤停期间及之后抗心律失常药物的使用

2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
指南 / 共识 · Circulation · 2018-01-01

该2018年AHA聚焦更新总结了心脏骤停期间及之后使用抗心律失常药物的最新证据与推荐。更新指出,对于电击难治性心室颤动/无脉性室性心动过速心脏骤停,施救者可考虑使用胺碘酮或利多卡因。

要点

  • 电击难治性室颤/无脉性室速心脏骤停可考虑胺碘酮或利多卡因。
  • 抗心律失常药物对患者结局的改善尚不明确。

核心结论

  • 对于电击难治性心室颤动/无脉性室性心动过速心脏骤停,施救者可考虑使用胺碘酮或利多卡因。

主要发现

  • 抗心律失常药物常用于心室颤动/无脉性室性心动过速心脏骤停期间及之后,但是否改善患者结局尚不明确。

关键数值与推荐

  • 修订推荐:施救者可考虑使用胺碘酮或利多卡因治疗电击难治性心室颤动/无脉性室性心动过速心脏骤停。

临床怎么用

  • 在电击难治性心室颤动/无脉性室性心动过速心脏骤停时,可考虑给予胺碘酮或利多卡因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Panchal AR, Berg KM, Kudenchuk PJ, et al. 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018. PMID: 30571262. doi:10.1161/CIR.0000000000000613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。